Skip to Content

uniQure NV QURE

Morningstar Rating
$5.20 −0.21 (3.88%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

QURE is trading within a range we consider fairly valued.
Price
$5.39
Fair Value
$87.47
Uncertainty
Extreme
1-Star Price
$852.40
5-Star Price
$4.15
Economic Moat
Hxt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QURE is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.41
Day Range
$5.165.40
52-Week Range
$4.7622.48
Bid/Ask
$4.95 / $5.21
Market Cap
$248.76 Mil
Volume/Avg
767,714 / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
15.65
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
480

Comparables

Valuation

Metric
QURE
NAMS
PHVS
Price/Earnings (Normalized)
Price/Book Value
1.206.765.84
Price/Sales
15.65137.91
Price/Cash Flow
Price/Earnings
QURE
NAMS
PHVS

Financial Strength

Metric
QURE
NAMS
PHVS
Quick Ratio
8.446.869.85
Current Ratio
8.856.9510.46
Interest Coverage
−6.85
Quick Ratio
QURE
NAMS
PHVS

Profitability

Metric
QURE
NAMS
PHVS
Return on Assets (Normalized)
−35.54%−34.73%−50.56%
Return on Equity (Normalized)
−82.34%−39.45%−56.14%
Return on Invested Capital (Normalized)
−55.12%−41.57%−56.14%
Return on Assets
QURE
NAMS
PHVS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRZqyfzmydvRkxd$570.1 Bil
VRTX
Vertex Pharmaceuticals IncXfkfxgqvRfbzdg$108.0 Bil
REGN
Regeneron Pharmaceuticals IncMqcndshYwqjz$105.6 Bil
MRNA
Moderna IncWrpcgkhwZbcxr$40.8 Bil
ARGX
argenx SE ADRCfgcswvqsKqzxh$23.5 Bil
BNTX
BioNTech SE ADRHkhtwfgndCfvbh$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncGlyjcmhkYsslqh$18.8 Bil
BMRN
Biomarin Pharmaceutical IncPcfvqyfBrwdw$16.5 Bil
RPRX
Royalty Pharma PLC Class AKllvxtkjfvMzsqk$13.6 Bil
INCY
Incyte CorpNryrnghdFzhrpv$12.8 Bil

Sponsor Center